EMERSON ELECTRIC CO — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that EMERSON ELECTRIC CO filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Sep 30, 2012 | $24.41B | Nov 20, 2012 |
| FY2012 | Sep 30, 2011 | $24.22B | Nov 20, 2012 |
| FY2012 | Sep 30, 2010 | $21.04B | Nov 20, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $4.86B | Nov 10, 2025 |
| FY2025 | Jun 30, 2025 | $4.55B | Nov 10, 2025 |
| FY2025 | Mar 31, 2025 | $4.43B | Nov 10, 2025 |
| FY2025 | Dec 31, 2024 | $4.18B | Nov 10, 2025 |
| FY2025 | Sep 30, 2024 | $4.62B | Nov 10, 2025 |
| FY2025 | Jun 30, 2024 | $4.38B | Nov 10, 2025 |
| FY2025 | Mar 31, 2024 | $4.38B | Nov 10, 2025 |
| FY2025 | Dec 31, 2023 | $4.12B | Nov 10, 2025 |
| FY2024 | Sep 30, 2023 | $4.09B | Nov 12, 2024 |
| FY2024 | Jun 30, 2023 | $3.95B | Nov 12, 2024 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Sep 30, 2018 | $4.89B | Nov 19, 2018 |
| FY2018 | Jun 30, 2018 | $4.46B | Nov 19, 2018 |
| FY2018 | Mar 31, 2018 | $4.25B | Nov 19, 2018 |
| FY2018 | Dec 31, 2017 | $3.82B | Nov 19, 2018 |
| FY2017 | Sep 30, 2017 | $4.44B | Nov 20, 2017 |
| FY2017 | Jun 30, 2017 | $4.04B | Nov 20, 2017 |
| FY2017 | Mar 31, 2017 | $3.57B | Nov 20, 2017 |
| FY2017 | Dec 31, 2016 | $3.22B | Nov 20, 2017 |
| FY2016 | Sep 30, 2016 | $3.93B | Nov 16, 2016 |
| FY2016 | Jun 30, 2016 | $3.67B | Nov 16, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $2.52B | Nov 10, 2025 |
| FY2025 | Jun 30, 2025 | $2.39B | Nov 10, 2025 |
| FY2025 | Mar 31, 2025 | $2.37B | Nov 10, 2025 |
| FY2025 | Dec 31, 2024 | $2.24B | Nov 10, 2025 |
| FY2025 | Sep 30, 2024 | $2.37B | Nov 10, 2025 |
| FY2025 | Jun 30, 2024 | $2.31B | Nov 10, 2025 |
| FY2025 | Mar 31, 2024 | $2.28B | Nov 10, 2025 |
| FY2025 | Dec 31, 2023 | $1.92B | Nov 10, 2025 |
| FY2024 | Sep 30, 2023 | $2.01B | Nov 12, 2024 |
| FY2024 | Jun 30, 2023 | $1.99B | Nov 12, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $637.00M | Nov 10, 2025 |
| FY2025 | Jun 30, 2025 | $586.00M | Nov 10, 2025 |
| FY2025 | Mar 31, 2025 | $485.00M | Nov 10, 2025 |
| FY2025 | Dec 31, 2024 | $585.00M | Nov 10, 2025 |
| FY2025 | Sep 30, 2024 | $996.00M | Nov 10, 2025 |
| FY2025 | Jun 30, 2024 | $329.00M | Nov 10, 2025 |
| FY2025 | Mar 31, 2024 | $501.00M | Nov 10, 2025 |
| FY2025 | Dec 31, 2023 | $142.00M | Nov 10, 2025 |
| FY2024 | Sep 30, 2023 | $744.00M | Nov 12, 2024 |
| FY2024 | Jun 30, 2023 | $9.35B | Nov 12, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $771.00M | Nov 10, 2025 |
| FY2025 | Sep 30, 2024 | $781.00M | Nov 10, 2025 |
| FY2025 | Sep 30, 2023 | $523.00M | Nov 10, 2025 |
| FY2024 | Sep 30, 2022 | $385.00M | Nov 12, 2024 |
| FY2023 | Sep 30, 2021 | $347.00M | Nov 13, 2023 |
| FY2022 | Sep 30, 2020 | $439.00M | Nov 14, 2022 |
| FY2021 | Sep 30, 2019 | $454.00M | Nov 15, 2021 |
| FY2020 | Sep 30, 2018 | $436.00M | Nov 16, 2020 |
| FY2019 | Sep 30, 2017 | $340.00M | Nov 18, 2019 |
| FY2018 | Sep 30, 2016 | $320.00M | Nov 19, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $5.10B | Nov 10, 2025 |
| FY2025 | Sep 30, 2024 | $5.14B | Nov 10, 2025 |
| FY2025 | Sep 30, 2023 | $4.19B | Nov 10, 2025 |
| FY2024 | Sep 30, 2022 | $3.61B | Nov 12, 2024 |
| FY2023 | Sep 30, 2021 | $3.49B | Nov 13, 2023 |
| FY2022 | Sep 30, 2020 | $3.99B | Nov 14, 2022 |
| FY2021 | Sep 30, 2019 | $4.46B | Nov 15, 2021 |
| FY2020 | Sep 30, 2018 | $4.27B | Nov 16, 2020 |
| FY2019 | Sep 30, 2017 | $3.61B | Nov 18, 2019 |
| FY2018 | Sep 30, 2016 | $3.46B | Nov 19, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $3.10B | Nov 10, 2025 |
| FY2025 | Sep 30, 2024 | $3.33B | Nov 10, 2025 |
| FY2025 | Sep 30, 2023 | $637.00M | Nov 10, 2025 |
| FY2024 | Sep 30, 2022 | $2.92B | Nov 12, 2024 |
| FY2023 | Sep 30, 2021 | $3.58B | Nov 13, 2023 |
| FY2022 | Sep 30, 2020 | $3.08B | Nov 14, 2022 |
| FY2021 | Sep 30, 2019 | $3.01B | Nov 15, 2021 |
| FY2020 | Sep 30, 2018 | $2.89B | Nov 16, 2020 |
| FY2019 | Sep 30, 2017 | $1.91B | Nov 18, 2019 |
| FY2018 | Sep 30, 2016 | $2.88B | Nov 19, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $431.00M | Nov 10, 2025 |
| FY2025 | Sep 30, 2024 | $419.00M | Nov 10, 2025 |
| FY2025 | Sep 30, 2023 | $363.00M | Nov 10, 2025 |
| FY2024 | Sep 30, 2022 | $299.00M | Nov 12, 2024 |
| FY2023 | Sep 30, 2021 | $404.00M | Nov 13, 2023 |
| FY2022 | Sep 30, 2020 | $538.00M | Nov 14, 2022 |
| FY2021 | Sep 30, 2019 | $594.00M | Nov 15, 2021 |
| FY2020 | Sep 30, 2018 | $617.00M | Nov 16, 2020 |
| FY2019 | Sep 30, 2017 | $476.00M | Nov 18, 2019 |
| FY2018 | Sep 30, 2016 | $447.00M | Nov 19, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $41.96B | Nov 10, 2025 |
| FY2025 | Sep 30, 2024 | $44.25B | Nov 10, 2025 |
| FY2025 | Sep 30, 2023 | $42.75B | Nov 10, 2025 |
| FY2024 | Sep 30, 2022 | $35.67B | Nov 12, 2024 |
| FY2023 | Sep 30, 2021 | $24.72B | Nov 13, 2023 |
| FY2022 | Sep 30, 2020 | $22.88B | Nov 14, 2022 |
| FY2021 | Sep 30, 2019 | $20.50B | Nov 15, 2021 |
| FY2020 | Sep 30, 2018 | $20.39B | Nov 16, 2020 |
| FY2019 | Sep 30, 2017 | $19.59B | Nov 18, 2019 |
| FY2018 | Sep 30, 2016 | $21.73B | Nov 19, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $20.28B | Nov 10, 2025 |
| FY2025 | Sep 30, 2024 | $21.64B | Nov 10, 2025 |
| FY2024 | Sep 30, 2023 | $20.69B | Nov 12, 2024 |
| FY2023 | Sep 30, 2022 | $10.36B | Nov 13, 2023 |
| FY2022 | Sep 30, 2021 | $9.88B | Nov 14, 2022 |
| FY2022 | Sep 30, 2020 | $8.41B | Nov 14, 2022 |
| FY2021 | Sep 30, 2019 | $8.23B | Nov 15, 2021 |
| FY2020 | Sep 30, 2018 | $8.95B | Nov 16, 2020 |
| FY2019 | Sep 30, 2017 | $8.72B | Nov 18, 2019 |
| FY2018 | Sep 30, 2016 | $7.57B | Nov 19, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $18.19B | Nov 10, 2025 |
| FY2025 | Sep 30, 2024 | $18.07B | Nov 10, 2025 |
| FY2025 | Sep 30, 2023 | $14.48B | Nov 10, 2025 |
| FY2024 | Sep 30, 2022 | $13.95B | Nov 12, 2024 |
| FY2023 | Sep 30, 2021 | $6.97B | Nov 13, 2023 |
| FY2022 | Sep 30, 2020 | $6.73B | Nov 14, 2022 |
| FY2021 | Sep 30, 2019 | $6.54B | Nov 15, 2021 |
| FY2020 | Sep 30, 2018 | $6.46B | Nov 16, 2020 |
| FY2019 | Sep 30, 2017 | $5.32B | Nov 18, 2019 |
| FY2018 | Sep 30, 2016 | $3.91B | Nov 19, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $40.60B | Nov 10, 2025 |
| FY2025 | Sep 30, 2024 | $40.83B | Nov 10, 2025 |
| FY2024 | Sep 30, 2023 | $40.07B | Nov 12, 2024 |
| FY2023 | Sep 30, 2022 | $28.05B | Nov 13, 2023 |
| FY2022 | Sep 30, 2021 | $26.05B | Nov 14, 2022 |
| FY2021 | Sep 30, 2020 | $24.96B | Nov 15, 2021 |
| FY2020 | Sep 30, 2019 | $24.20B | Nov 16, 2020 |
| FY2019 | Sep 30, 2018 | $23.07B | Nov 18, 2019 |
| FY2018 | Sep 30, 2017 | $22.00B | Nov 19, 2018 |
| FY2017 | Sep 30, 2016 | $21.72B | Nov 20, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Sep 30, 2021 | $2.35B | Nov 14, 2022 |
| FY2022 | Sep 30, 2020 | $3.32B | Nov 14, 2022 |
| FY2022 | Sep 30, 2019 | $1.49B | Nov 14, 2022 |
| FY2021 | Sep 30, 2018 | $1.09B | Nov 15, 2021 |
| FY2020 | Sep 30, 2017 | $3.06B | Nov 16, 2020 |
| FY2019 | Sep 30, 2016 | $3.18B | Nov 18, 2019 |
| FY2018 | Sep 30, 2015 | $3.05B | Nov 19, 2018 |
| FY2017 | Sep 30, 2014 | $3.15B | Nov 20, 2017 |
| FY2016 | Sep 30, 2013 | $3.28B | Nov 16, 2016 |
| FY2015 | Sep 30, 2012 | $2.37B | Nov 18, 2015 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $8.92B | Nov 10, 2025 |
| FY2025 | Sep 30, 2024 | $7.69B | Nov 10, 2025 |
| FY2024 | Sep 30, 2023 | $8.16B | Nov 12, 2024 |
| FY2023 | Sep 30, 2022 | $8.78B | Nov 13, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 1 | Nov 10, 2025 |
| FY2025 | Jun 30, 2025 | 1 | Nov 10, 2025 |
| FY2025 | Mar 31, 2025 | 0 | Nov 10, 2025 |
| FY2025 | Dec 31, 2024 | 1 | Nov 10, 2025 |
| FY2025 | Sep 30, 2024 | 1 | Nov 10, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Nov 10, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Nov 10, 2025 |
| FY2025 | Dec 31, 2023 | 0 | Nov 10, 2025 |
| FY2024 | Sep 30, 2023 | 1 | Nov 12, 2024 |
| FY2024 | Jun 30, 2023 | 16 | Nov 12, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 1 | Nov 10, 2025 |
| FY2025 | Jun 30, 2025 | 1 | Nov 10, 2025 |
| FY2025 | Mar 31, 2025 | 0 | Nov 10, 2025 |
| FY2025 | Dec 31, 2024 | 1 | Nov 10, 2025 |
| FY2025 | Sep 30, 2024 | 1 | Nov 10, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Nov 10, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Nov 10, 2025 |
| FY2025 | Dec 31, 2023 | 0 | Nov 10, 2025 |
| FY2024 | Sep 30, 2023 | 1 | Nov 12, 2024 |
| FY2024 | Jun 30, 2023 | 16 | Nov 12, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 562.80M | Nov 10, 2025 |
| FY2025 | Sep 30, 2024 | 570.20M | Nov 10, 2025 |
| FY2024 | Sep 30, 2023 | 572.00M | Nov 12, 2024 |
| FY2023 | Sep 30, 2022 | 591.40M | Nov 13, 2023 |
| FY2022 | Sep 30, 2021 | 595.80M | Nov 14, 2022 |
| FY2021 | Sep 30, 2020 | 598.00M | Nov 15, 2021 |
| FY2020 | Sep 30, 2019 | 611.00M | Nov 16, 2020 |
| FY2019 | Sep 30, 2018 | 629.20M | Nov 18, 2019 |
| FY2018 | Sep 30, 2017 | 641.70M | Nov 19, 2018 |
| FY2017 | Sep 30, 2016 | 642.80M | Nov 20, 2017 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.19B | Nov 10, 2025 |
| FY2025 | Sep 30, 2024 | $1.20B | Nov 10, 2025 |
| FY2025 | Sep 30, 2023 | $1.20B | Nov 10, 2025 |
| FY2024 | Sep 30, 2022 | $1.22B | Nov 12, 2024 |
| FY2023 | Sep 30, 2021 | $1.21B | Nov 13, 2023 |
| FY2022 | Sep 30, 2020 | $1.21B | Nov 14, 2022 |
| FY2021 | Sep 30, 2019 | $1.21B | Nov 15, 2021 |
| FY2020 | Sep 30, 2018 | $1.23B | Nov 16, 2020 |
| FY2019 | Sep 30, 2017 | $1.24B | Nov 18, 2019 |
| FY2018 | Sep 30, 2016 | $1.23B | Nov 19, 2018 |